Management of thrombosis in antiphospholipid antibody syndrome

M. Petri

doi:10.1016/S0889-857X(05)70225-8

Management of thrombosis in antiphospholipid antibody syndrome

M. Petri

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Antiphospholipid antibody positive patients are at risk for venous and arterial thrombosis. The risk of recurrent thromboembolism is high. Although the standard of care is high intensity warfarin after a thromboembolic event, some studies indicate that this degree of anticoagulation is not needed. There is an urgent need of clinical trials to address management of thrombosis in antiphospholipid syndrome.

Original language	English (US)
Pages (from-to)	633-642
Number of pages	10
Journal	Rheumatic Disease Clinics of North America
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/S0889-857X(05)70225-8
State	Published - Jan 1 2001
Externally published	Yes

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/S0889-857X(05)70225-8

Cite this

@article{e90ddfbd3e484e3a89aa054860f6cafa,

title = "Management of thrombosis in antiphospholipid antibody syndrome",

abstract = "Antiphospholipid antibody positive patients are at risk for venous and arterial thrombosis. The risk of recurrent thromboembolism is high. Although the standard of care is high intensity warfarin after a thromboembolic event, some studies indicate that this degree of anticoagulation is not needed. There is an urgent need of clinical trials to address management of thrombosis in antiphospholipid syndrome.",

author = "M. Petri",

year = "2001",

month = jan,

day = "1",

doi = "10.1016/S0889-857X(05)70225-8",

language = "English (US)",

volume = "27",

pages = "633--642",

journal = "Rheumatic Disease Clinics of North America",

issn = "0889-857X",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Management of thrombosis in antiphospholipid antibody syndrome

AU - Petri, M.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Antiphospholipid antibody positive patients are at risk for venous and arterial thrombosis. The risk of recurrent thromboembolism is high. Although the standard of care is high intensity warfarin after a thromboembolic event, some studies indicate that this degree of anticoagulation is not needed. There is an urgent need of clinical trials to address management of thrombosis in antiphospholipid syndrome.

AB - Antiphospholipid antibody positive patients are at risk for venous and arterial thrombosis. The risk of recurrent thromboembolism is high. Although the standard of care is high intensity warfarin after a thromboembolic event, some studies indicate that this degree of anticoagulation is not needed. There is an urgent need of clinical trials to address management of thrombosis in antiphospholipid syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0034865787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034865787&partnerID=8YFLogxK

U2 - 10.1016/S0889-857X(05)70225-8

DO - 10.1016/S0889-857X(05)70225-8

M3 - Article

C2 - 11534265

AN - SCOPUS:0034865787

SN - 0889-857X

VL - 27

SP - 633

EP - 642

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

IS - 3

ER -

Management of thrombosis in antiphospholipid antibody syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this